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ABSTRACT 
PURPOSE OF THE REVIEW: Anaplastic Large Cell Lymphomas (ALCLs) are rare entities 
whose tumorigenic events have only been found in well-defined subsets. The categorization of 
additional molecular fingerprints is needed to advance our knowledge and to deliver successful 
therapies. 
RECENT FINDINGS: The discovery of Anaplastic Lymphoma Kinase (ALK) fusions has 
provided the basis for the characterization of distinct subsets among ALCL patients. Although the 
oncogenic addiction of ALK signaling is proven, the tumorigenic contribution of co-activating 
lesions is still missing. As ALK- and ALK+ share common signatures, it is plausible that analogous 
mechanisms of transformation may be operating in both subsets, as confirmed by the dis-regulated 
activation of c-MYC, and the loss of Blimp-1 and p53/p63 axis. Nonetheless, recurrent genetic 
alterations for ALK- ALCL or refractory leukemic ALK+ ALCL are lacking. Moreover, although 
conventional chemotherapies (anthracycline-based) are most successful, i.e. in ALK+ ALCL 
patients, the implementation of ALK inhibitors or of anti-CD30 based treatments provides 
innovatites solutions, particularly in pediatric ALK+ ALCL and in chemorefractory/relapsed 
patients.  
SUMMARY: The complete portrayal of the landscape of genetic alterations in ALCL will dictate 
the development of innovative chemotherapeutic and targeted therapies that will fit most with the 
molecular and clinical profiling of individual patients. 
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KEY POINTS:  
 
• Anaplastic Large Cell Lymphoma are an heterogeneous group of lymphoma some of which 
carry a restricted number of genetic defects mainly involving the Anaplastic Lymphoma Kinase 
(ALK+ ALCL) o less frequently display alternative translocations [t(2;x)(p23;x), 
t(6;7)(p25.3;q32.3) and inv(3)(q26q28) leading to TBL1XR1/TP63, etc.]. Nonetheless, specific 
lesions are still lacking for many ALCLs. 
• The precise relationship and origin of ALCL remain unclear. Although ALK+ and ALK- share 
a set of genes and similar phenotypes, they are considered distinct groups with unique clinical 
features. However, it is unknown whether clinical differences and responses to conventional 
therapies may simply be related to different clinical stages and/or  unique genomic lesions. 
• Bioinformatics algorithms have identified several ALCL signaling classifiers demonstrating the 
preferential expression of a restricted number of pathways. The recognition of “common hubs”, 
which can be targeted by selective inhibitors, represents a viable strategy for future therapeutic 
protocols. 
• Taking advantage of in vitro and in vivo models, several groups have shown that the 
transforming properties of ALK fusions involve a plethora of alternative modules capable to 
regulate intrinsic (i.e. cytoskeleton, cell growth, etc.) and/or extrinsic (cell matrix invasion, 
tumor-host relationships, etc.) modalities. 
• The identification of the driving lesion of ALCL will require the construction of international 
networks capable to synergize their activities and to construct large and clinically annotate 
tissue libraries. The collection of viable tissues will facilitate the generation of batteries of 
“Patient Derived Tumorgrafts”.  
 
INTRODUCTION 
Peripheral T-cell lymphoma (PTCL) are a heterogeneous group of tumors derived from post-
thymic elements including leukemic/disseminated, nodal and extranodal diseases [1,2,3]. As 
orphan diseases (12 to 15% of all non-Hodgkin’s lymphoma [NHL] in Western populations) 
[1,2,3,4], they include entities displaying a great variability in clinical, morphological, 
immunophenotypic, cytogenetic and molecular features. First described in 1985 [5], Anaplastic 
Large Cell Lymphoma (ALCL) of either adults (2-8% of NHL) or children (15-30% of NHL), 
nowadays correspond to specific subtypes of systemic peripheral T-cell lymphoma [1]. The 
presence of Anaplastic Lymphoma Kinase (ALK) gene fusions has provided the criteria for a 
new WHO classification, which contemplates a novel entity (i.e. ALCL ALK+) and proposes a 
provisional one, including ALCL patients, who lack ALK translocations (i.e. ALCL ALK-). 
Because of genetic, immunophenotypic, and clinical differences, cutaneous ALCLs (cALCL) are 
considered as a completely distinct subset a part from its systemic counterparts. Systemic ALCL 
share cytological, immunophenotypic and molecular features. However, ALK- ALCL patients 
have poorer performance status, more often B symptoms [6], and an overall survival (OS) rate of 
36% versus 20% of PTCL-NOS patients. This suggests unique driving defects, with high 
oncogenic penetrance. In contrast, ALK+ ALCL have a more favorable clinical course [4], 
though ALK+ ALCL with an aggressive behavior could be encountered in the clinical practice 
[7]. It remains uncertain whether the molecular lesion(s) and/or other features determine the 
clinical course of ALCL patients. In fact, once patients are normalized by clinical parameters, 
ALK- and ALK+ ALCL display analogous prognosis (failure-free survival [FFS] and OS) [6].  
Considering that ALK+ ALCL have a less complex karyotype [8,9,10,11], it plausible that ALK 
fusions are critical actors and that tumor progression is due to somatic mutations (minimal 
deletions, activating somatic mutations, etc.) disrupting the function of a limited set of genes. In 
contrast, the transformation of ALK- ALCL might require the consolidation/acquisition of many 
genetic defects that rapidly lead to systemic and more aggressive phenotype. This is in 
agreement suggested with their higher and heterogeneous karyotypes [8,9,10,11]. Nonetheless, 
the driving lesion(s) of ALK- ALCL are still to be identified, and co-drivers are lacking for both 
ALCL subgroups.  
The lack of representative cell lines or animal models has definitively contributed in impairing 
our knowledge of mature T-cell lymphoma. Ultimately, this has jeopardized the design of 
successful therapies and the upgrade of clinical programs, particularly in patients with poor 
outcome (ALK- ALCL and PTCL-NOS). The recognition of the tumorigenic defects of PTCL is 
expected to provide patient specific "molecular fingerprints" and thus more suitable tailored 
therapies.  
 
ONCOGENIC SIGNALING OF ALK FUSIONS 
Chromosomal translocations of the ALK gene are documented in many ALCL, although the 
percentage of ALK+ ALCL varies, as a result of the inclusion criteria of the ALK- ALCL. In 
absence of strong classifier(s) (like ALK), the distinction between ALK- ALCL, CD30 PTCL-
NOS and some enteropathy associated T-cell lymphoma represents a diagnostic challenge.  
ALK gene encodes a 210 kDa tyrosine kinase receptor (CD247) belonging to the insulin growth 
factor receptor superfamily. Its expression is largely limited to the nervous system during 
embryogenesis and to focal areas of the adult brain [12]. Although the physiological role of ALK 
in mammals is unknown, it is involved in neuronal differentiation [13] and ALK activating 
mutations have been found in familial and sporadic neuroblastomas [14].  
The breakpoints of ALK chimera invariably occur within the intron placed between the exons 19 
and 20 (NM_004304.3). Thus exons coding for the intracytoplasmic domain of ALK (exons 20–
29) are then juxtaposed to different partners [15,16]. Seventy-80% of ALK+ ALCL harbor the 
t(2;5)(p23;q35) translocation (NPM–ALK chimera). The intracellular distribution of the fusions 
is due to the structure/function of ALK partners, enforcing either to nuclear/cytoplasmic, or 
cytoplasmic and in rare cases juxta-membranous localization.  Virtually all partners (with the 
exclusion of MYH9-ALK) provide dimerization domains, leading to the 
homo/heterodimerization of the fusions and to constitutive activation of the kinase [16,17]. 
Conventional genomic approaches, and more recently next generation sequencing (NGS) have 
shown alternative ALK translocations in many types of human cancers, e.i. lung tumors [18,19].  
ALCL display additional alterations involving many chromosomes [8,9,10,20], however 
frequent common/discrete secondary lesions are rare. Two translocations were reported in ALK-
ALCL, involving the DUSP22 gene, which is juxtaposed to the FRA7H fragile site, or to the 
gene coding for IRF4 [21]. Boi et al. have recently shown that several ALCL display recurrent 
deletions affecting 17p13.3-p12 (25%) region, in which TP53 gene is located, and 6q21 (19%) 
encompassing PRDM1 and ATG5 genes [11].  Finally, Vaismatzis et al. have recently described 
a set of genomic defects in DLBCL and PTCL/ALCL encoding fusion proteins homologous to 
ΔNp63, a dominant-negative p63 isoform that inhibits the p53 pathway [22]. 
ALK chimera were originally proven to be oncogenic in vivo [23] and these data were largely 
confirmed in in vitro models [24] and then in genetically modified animals [25,26]. 
Understanding how ALK signals acts and defining the mechanisms responsible for its 
deregulation is critical for dissecting the mechanisms, which mediate ALK cellular 
transformation and provide the basis for rationale therapeutic approaches. By a large array of 
methods, it is now know that ALK fusions and in particular the NPM-ALK chimera interact with 
a plethora of molecules and elicit many pathways. These include the RAS/Erk, PLC-γ, PI3K, and 
Jak/Signal Transducers and Activators of Transcription (STAT), capable to control individually 
or in association, cell proliferation, survival, and cytoskeletal properties [19].  
The activation of RAS/Erk pathway provides positive signals regulating cell growth and the 
inhibition of MEK (AZD6244 or shRNA) leads to cell cycle arrest, without significant changes 
in cell viability (Crescenzo R, personal communication). Similarly, NPM-ALK can down-
modulate, via PI3K-AKT, the inhibitory action of FOXO3a, upregulating Cyclin D2 and down-
regulating p27, and providing positive growth signals.  
We and other groups have shown that the neoplastic phenotype of NPM-ALK is largely 
mediated by the STAT3. This enforces the transcription of a surplus of genes (coding and non 
coding), promoting cell growth and survival. In shRNA-based knockdown experiments, Piva et 
al. have demonstrated that several genes are directly regulated by STAT3, which display 
canonical STAT3 binding sites within their regulatory regions (Piva R, personal 
communication). Among them we mention CD30, granzyme, perforin, IL1RAP and IL2RA. 
From a diagnostic point of view, CD30, granzyme, perforin are known to be preferentially 
expressed by ALCL cells, and are commonly used in algorithms encompassing the differential 
diagnosis of different PTCL entities. Their transcription requires phosphorylated STAT3 
complexes, which often include CEBPb and AP-1 transcription factors. Notably AP-1 members 
play an important role in ALK mediated transformation controlling tumor growth and positive 
host signals, via PDGF [27] (Fig. 1).  
Zhang and coworkers have recently elucidated additional features of STAT3, demonstrating a 
STAT3-positive regulation of ICOS [28]. The same group had previously shown that PDL-1 
expression is also regulated by STAT3 [29]. Collectively, these data demonstrate that ALCL 
cells engage ICOS to gain a growth advantage, and PDL-1 as novel mechanism of tumor escape, 
modulating the host responses. The overexpression of IL-21 [30] and deregulation of 
TNF/Fas/TNF [31] can also contribute to ALK tumorigenic phenotype, favoring the success of 
ALCL cells and overcoming host defenses.  Finally, ALK signaling controls HiF1α, a factor that 
impacts directly in the neo-angiogenesis and provides a positive growth advantage to the 
lymphoma cells [32,33] (Fig. 1).  
Lastly, STAT3 itself can directly or via downstream mediators down-regulate the transcription 
of many genes. Approximately 60% of modulated STAT3 genes are repressed after shRNA KD. 
Interestingly, Zhang et al have recently reported that STAT3, engaging the IL-2Rγ promoter, 
enhances the binding of DNA methyltransferases (DNMTs), leading ultimately to the 
transcriptional repression of IL-2Rγ gene. The knockdown of IL-2Rγ expression contributes to 
the neoplastic phenotype, as demonstrated by its forced/expression that leads to the loss of NPM-
ALK protein expression, and then apoptosis. Ultimately, STAT3 down regulates T-cell 
associated molecules controlling T-cell identity of ALCL cells. In this context NPM-ALK 
provides signals capable to bypass TCR mediated activation [34,35] (Fig. 1).  
STAT3 can similarly regulate the expression of several miRNA clusters (Spaccarotella E, 
personal communication) including the miRNA17-92 [36], known to have a role in human 
cancers. In ALCL, the miRNA17-92 overexpression overcomes in part the loss of STAT3 in an 
shRNA STAT3 inducible ALK+ ALCL model. More importantly, primary ALK+ ALCL display 
higher miRNA17-92 levels [36] compared to ALK- ALCL and cutaneous T-cell lymphoma and 
the usage of STAT3 inhibitors leading to the down-regulation of this cluster could represent an 
attractive strategy for the treatment of ALCL lymphoma (Lin C, personal communication).  
The ability to successfully migrate and invade distant tissues contributes to the neoplastic 
phenotype, impairing clinical responses and long remissions. ALK signaling can efficiently 
module the cytoskeleton and promote invasion. The data reported by Ambrogio et al. [37] have 
recently been confirmed [38]. Dupuis-Coronas et al. have also shown that ALK, modulating the 
activity of PIKfyve, enhances the invasive capacities of NPM-ALK cells and their capacity to 
degrade the extracellular matrix [39]. Invasion of ALK+ ALCL cells is also modulated by the 
axis ALK-STAT3-Twist1 [40] (Fig. 1).  
In conclusion, it is evident that the tumorigenic properties of ALK signaling are more complex 
that originally proposed, confirming that ALK is a powerful kinase capable to provide a 
complete and broad oncogenic addiction. These properties make ALK an excellent therapeutic 
target.  
 
ALKR AND ALKS ANAPLASTIC LARGE CELL LYMPHOMAS: TWO SIDES OF THE 
SAME  COIN? 
The debate on distinct entities among PTCLs remains open.  Novel hypotheses are emerging on 
the origin and relationship of different PTCL entities. The concept that ALK- ALCL should be 
lumped within PTCL-NOS has been recently sponsored. Alternatively, a scenario in which all 
ALCL are incorporated in a single group, irrespectively of the ALK expression has been 
contemplated. This level of uncertainty is corroborated by the fact that, once ALCL patients are 
stratified by stage, IPI etc. either groups display similar characteristics. In this landscape, CD30+ 
PTCL represent a puzzling/confounding group [41]. Their precise definition is critical and 
sometime questionable. Immunophenotypically, they express weak/partial CD30, and in same 
cases CD15 [42,43]. Cytologically display a certain monomorphism and they often have a 
functional TCR signaling (NFATc positive etc.) [44,45]. Clinically, CD30+ PTCL share a more 
aggressive clinical course, justifying their distinction and a closer relationship to PTCL-NOS. 
We strongly believe that these uncertainties will be solved only when distinct molecular defects 
will be discovered in different PTCLs.  
Another similar confusing topic regards the ALCL origin, and their putative normal counterpart 
elements. Several hypotheses have been proposed, taking in account their expression profile and 
unique immune-phenotype. The expression of perforin, T1A1 and granzyme has been interpreted 
as a specific fingerprint, supporting the idea that ALCL may derive from cytotoxic T-
lymphocytes. Alternatively, we speculate that the phenotype of ALCL may rather be the result of 
the deregulated expression of unique pathways and/or specific defects, which impose 
unique/fixed profiles. It is known that transcription factors can play a critical role in T-cell 
differentiation and once constitutively activated can undermine physiological programs and 
rerouted their development. Based on this assumption, we could speculate that the constitutive 
activation of STAT3 might be responsible for the cytotoxic phenotype of ALK+ ALCL cells, 
even in cells that were committed to different lineages and/or function. This leaves the open 
question, why ALK- ALCL display a cytotoxic phenotype? To solve this question, we have 
analyzed a large cohort of ALCL samples and found that a subset of ALK- ALCL clearly shares 
a STAT3 expression profile and detectable nuclear pSTAT3. Moreover, both ALK+ and ALK- 
ALCL reveal signatures, linked to the activation of c-MYC, NOTCH-1, or NFkB, and 
RAS/ERK, suggesting the existence of upstream activators. Interestingly, it now evident that 
several ALCL co-share overlapping signatures suggesting multiple activating defects or 
alternatively the presence of unique lesions capable, like ALK fusions, to efficiently and 
concomitantly fire multiple pathways. Search of ALCL pathogenetic lesions is under evaluation 
and it is predicted that new information will be available soon (Fig. 2).  
 
CAN WE USE PRECISION MEDICINE DATA TO IMPROVE THERAPUTIC 
COMPLIANCE? 
The definition of the molecular fingerprints of neoplasms is now possible through the 
implementation of the impressive technologies. The NGS platforms are currently entering the 
clinical arena and it is plausible that, once interconnected and clinical based networks of 
laboratories, many patients will have individualized molecular identikits. Nonetheless, caveats 
on the tumorigenic contribution of individual lesions and their functional role in the maintenance 
of the neoplastic phenotypes remain untouched. This are a critical issues, which should be added 
to the overwhelming capacity of tumor cells to adapt rapidly to the environment and to stress 
imposed by drugs and host changes. Thus, the search the “magic bullet” may fail. Instead, the 
association of multiple “smart” compounds could provide higher response rates and overcome 
resistance. Since the cost for a novel drug is around 1billion and requires approximately 12-15 
years, we need to overcome impairing inefficiencies. It is agreed that many improvements in 
discovery programs need to be rapidly put in place, meliorating company inefficiencies 
(structural and operation), selection of viable targets, defining good therapeutic biopredictors, 
innovative technologies, more efficient and reliable screening tests and faster and less expensive 
clinical tracks in molecularly defined and/or naïve patients. 
While pharmaceutical companies are reshaping their pipelines, a small number of drugs is 
successfully introduced into clinics. This ineffective result is seemingly related to update pre-
clinical models, heavily relaying on in vitro models and “xenografts mouse platforms”.  Indeed, 
the most frequently used cell lines poorly represent human tumors [46]. This has encouraged 
many institutions and drug industry to acquire large library of cell lines, which can be 
interrogated with HTP platforms (NSG, phosphomapping etc.). The hope is to define better 
criteria and relationships between the genome and responses to therapies. The hope is of 
predicting more reliable clinical responses and dissecting responders and refractory patients. But, 
cell lines lack the host and its regulatory networks, have undergone ferocious in vitro selections 
and do not represent tumor heterogeneity.  
To solve some of these issues, implants of fresh primary neoplasms are frequently introduced in 
severally-immunocompromised mice [47]. The generation of individualized cancer models 
represents an unprecedented opportunity to test battery of drugs for each individual and provide 
personalized oncology programs.  However, these strategies need to be linked to defined genetic 
defects. Only combining HTP and innovative models, we can deliver a list of targetable lesions, 
which once validated in animals, should provide reasonable expectations. Since the successful 
growth of tumorgraft implants may require long period of time, new technologies interrogating 
the functional network in cancer and the efficacy of chemical libraries in vitro may provide 
alternative routes for the execution of pre-clinical trials in vivo. Our group has recently embarked 
in such a program and generated a battery of ALCL “Patients Derived Tumorgrafts” (PDT) [48]. 
These retain the immunophenotypic, genomic features of their corresponding primary tumors 
and display responses to conventional and innovative protocols that closely mimic those seen in 
donor patients. Their molecular characterization has demonstrated the presence of unique 
genomic defects and allowed to discover new pathogenetic translocations and activating somatic 
mutations. The definition of a molecular identikit in PDTs will provide not only patients’ 
fingerprints but also models to test the efficacy of selected drugs targeting hypothetical 
tumorigenic defects in each patient in vivo.  
 
 
CONCLUSION 
 
Little  is yet known of mechanisms leading to T-cell lymphomagenesis.   Nonetheless,   the    
systematic usage   of  high throughput  platforms has  recently demonstrated that recurrent 
defects may  be present in  specific subsets of PTCLs. Although ALKþ ALCL and ALK-  ALCL  
display heterogeneous  complex karyotypes, they  share  common expression signa-  tures  and  
dysregulated signalling pathways. The use  of  NGS  approaches  will  be  instrumental for the 
more complete discovery of mechanisms driving the  pathogenesis of ALCL.  New  molecular 
lesions, even in  small subgroups of  patients, will  provide objective diagnostic criteria and the  
bases for ‘intelligent’ therapies, to  be  first  validated in  the  most informative preclinical 
models (i.e. PDT and so on) 
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FIGURE 1. Anaplastic large cell lymphoma cells dysregulate and control the host environment.  
The oncogenic drivers of ALCL reroute intrinsic pathways leading to a self-autonomous cell 
growth as well as overcome host confinements, modulating immuno-responses of regulatory and 
effector T-cells. This is accomplished through alternative mechanisms including antigen- 
camouflaging and lymphokines production obliterating immune surveillance (i.e. TNF/FasR,  
PD-L1/PD-L1R). Through cytoskeleton changes and production of pro-invasive mechanisms, 
tumour cells have the ability to migrate locally and disseminate to distant organs. Production of 
pro-angiogenetic  factors stimulates vessel formation providing the necessary growth support for 
tumour survival. The JAK – STAT signaling pathway represents a master culprit modulating 
gene expression transcription of critical players. ALCL, anaplastic large cell lymphoma; CDC42, 
cell division control protein 42 homolog; FasR, FAS receptor; HIF1a, hypoxia-inducible factor 1 
alpha; IL, interleukin; JAK, Janus kinase; MMPs, matrix metalloproteinases; PDGF, platelet-
derived  growth factor; PD-L1, programmed cell death 1 ligand 1; PIKfyve, finger-containing  
phosphoinositide kinase; pSTAT3, phosphorylated signal transducer and activator of 
transcription 3; TNF, tumour necrosis factor; TWIST1, twist-related protein 1; VEGF, vascular 
endothelial growth factor. 
 
 
 
 
FIGURE 2. Tumourigenic model for anaplastic large cell lymphoma transformation.  ALCL 
may derive from a common stem cell precursor or alternatively from partially committed  T 
element(s). Through  the acquisition of powerful oncogenetic drivers, ALCL cells acquire unique 
phenotypes and display restricted signaling pathways. The progressive  acquisition of selected 
genetic defects (loss of TP53, TP63, BLIMP1 and constitutive activation of c-MYC) is 
eventually responsible for tumour progression and more aggressive clinical behaviours.  ALCL, 
anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; IRF4, interferon regulatory 
factor 4; PRDM1,  PR domain zinc finger protein 1; STAT3, signal transducer and activator of 
transcription; TKR, tyrosine kinase receptor; TP, tumour  protein. 
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